WallStSmart

Merck & Company Inc (MRK)vsPlus Therapeutics Inc (PSTV)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 1269063% more annual revenue ($65.77B vs $5.18M). MRK leads profitability with a 13.6% profit margin vs -230.2%. PSTV appears more attractively valued with a PEG of 2.45. MRK earns a higher WallStSmart Score of 50/100 (D+).

MRK

Hold

50

out of 100

Grade: D+

Growth: 3.3Profit: 8.0Value: 2.7Quality: 5.0
Piotroski: 3/9Altman Z: 2.30

PSTV

Avoid

20

out of 100

Grade: F

Growth: 5.3Profit: 2.0Value: 6.3Quality: 6.5
Piotroski: 4/9Altman Z: -46.61
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MRKSignificantly Overvalued (-49.3%)

Margin of Safety

-49.3%

Fair Value

$80.88

Current Price

$120.79

$39.91 premium

UndervaluedFair: $80.88Overvalued

Intrinsic value data unavailable for PSTV.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MRK3 strengths · Avg: 9.3/10
Market CapQuality
$285.64B10/10

Mega-cap, among the largest globally

Operating MarginProfitability
38.6%10/10

Strong operational efficiency at 38.6%

Free Cash FlowQuality
$2.93B8/10

Generating 2.9B in free cash flow

PSTV2 strengths · Avg: 10.0/10
P/E RatioValuation
0.3x10/10

Attractively priced relative to earnings

Debt/EquityHealth
0.0610/10

Conservative balance sheet, low leverage

Areas to Watch

MRK4 concerns · Avg: 3.5/10
P/E RatioValuation
32.6x4/10

Premium valuation, high expectations priced in

Revenue GrowthGrowth
4.9%4/10

4.9% revenue growth

Debt/EquityHealth
1.073/10

Elevated debt levels

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

PSTV4 concerns · Avg: 3.3/10
PEG RatioValuation
2.454/10

Expensive relative to growth rate

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$37.86M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-99.8%2/10

ROE of -99.8% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.

Bull Case : PSTV

The strongest argument for PSTV centers on P/E Ratio, Debt/Equity.

Bear Case : MRK

The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.

Bear Case : PSTV

The primary concerns for PSTV are PEG Ratio, EPS Growth, Market Cap.

Key Dynamics to Monitor

MRK profiles as a value stock while PSTV is a turnaround play — different risk/reward profiles.

PSTV carries more volatility with a beta of 1.37 — expect wider price swings.

MRK is growing revenue faster at 4.9% — sustainability is the question.

MRK generates stronger free cash flow (2.9B), providing more financial flexibility.

Bottom Line

MRK scores higher overall (50/100 vs 20/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Plus Therapeutics Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacturing, and commercialization of treatments for patients with cancer and other diseases. The company is headquartered in Austin, Texas.

Want to dig deeper into these stocks?